search
Back to results

Mobile Health Technology for Chronic Kidney Disease Patients: Medication Management

Primary Purpose

Renal Insufficiency, Chronic, Hypertension, Medication Reconciliation

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Usual Care
Integrated mobile medication app
Commercially available mobile medication app
Sponsored by
University Health Network, Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Renal Insufficiency, Chronic focused on measuring chronic kidney disease, mobile applications, mHealth, medication reconciliation, self-management

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Incident or prevalent patients who are: ≥18 years of age
  • English-speaking
  • Able and willing to provide informed consent

Exclusion Criteria:

  • CKD stages 1 to 3a (estimated glomerular filtration rate of ≥ 45 ml/min)
  • likely to receive a kidney transplant within 3 months of enrollment into the trial
  • living in a long-term care or rehabilitation institution, likely to have their care transferred to another facility outside participating clinic areas during the course of the study
  • taking less than 2 prescription medications
  • planning to travel or live consecutively out of the province of Ontario for more than one month
  • participating in another intervention trial,
  • cognitive impairment

Sites / Locations

  • University Health Network

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

eKidneyCare

My MedRec (Commercial App)

Arm Description

The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.

My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.

Outcomes

Primary Outcome Measures

Medication Discrepancy
The change in unintentional medication discrepancy rate from baseline to the last (12 months) visit.

Secondary Outcome Measures

Clinic Blood Pressure
Mean change in systolic and diastolic BP measured by clinic BP Tru automated machine
Ambulatory Blood Pressure
Mean change in systolic and diastolic BP measured by average 7 day home ambulatory BP readings
CKD specific laboratory values (hemoglobin)
Proportion of patients in target hemoglobin, defined as hemoglobin of 100 to 120 g/L
CKD specific laboratory values (potassium)
Proportion of patients in target potassium ; defined as potassium of 3.2 to 5.0 mmol/L
CKD specific laboratory values (phosphate)
Proportion of patients in target phosphate; defined as phosphate range of less than 1.5 mmol/L.
Medication Discrepancy Proportion of Patients
Proportion of patients more than 1 unintentional discrepancy
Satisfaction
Key feedback on usability, experience and perceived strengths and weakness of mobile app
Quality of Life
Change in health utility scores as captured in the EQ-5D questionnaire

Full Information

First Posted
September 14, 2016
Last Updated
November 7, 2017
Sponsor
University Health Network, Toronto
Collaborators
Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT02905474
Brief Title
Mobile Health Technology for Chronic Kidney Disease Patients: Medication Management
Official Title
Harnessing Mobile Health Technology to Personalize the Care of Chronic Kidney Disease Patients: Medication Domain Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
May 2016 (undefined)
Primary Completion Date
September 26, 2017 (Actual)
Study Completion Date
September 26, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Health Network, Toronto
Collaborators
Canadian Institutes of Health Research (CIHR)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with complex, long-lasting conditions such as chronic kidney disease (CKD) often take multiple medications and frequently have serious medication problems, arising from poor communication between doctors and patients. Prescription errors or misunderstandings can cause harm and lead to emergency room visits or even hospitalizations. To address these issues, medication reconciliation is now used by hospitals as a way to confirm the medication list of patients on admission to and discharge from hospital. However, a similar process does not exist outside the hospital setting. In recent years patients have become more proactive in undertaking activities with a direct bearing on their health. Such activities may include maintaining an accurate list of their medications. The rapid growth of the digital health arena has led to the development of a large number of commercially available mobile medication management apps for patients. These digital tools are 'stand-alone' products that are not integrated with the patients' pharmacy or health record system. They rely on patients to enter the list of their medications and update it as necessary. Moreover, few have a function to communicate medication changes or problems with their healthcare providers. Recently, an integrated smartphone, eKidneyCare, app system was developed with a medication management feature to help patients maintain an accurate mobile medication list. Patients' current medication information in the pharmacy database is uploaded onto their by a pharmacist and changes are tracked regularly through a bi-directional communication system. Updates to the medication list occur seamlessly by the pharmacist, and patients and their physicians are notified about any medication errors or serious adverse events. This study will determine whether our eKidneyCare app with its medication management feature will decrease medication errors and improve patient safety compared to the more traditional way of managing medications.
Detailed Description
Background: Patients who have complicated conditions such as chronic kidney disease (CKD) are at high risk for problems related to their medications. Often these problems occur because doctors and patients do not communicate the right type of medication information to each other. This causes many prescribing errors and can lead to patient harm, emergency visits, or hospitalizations. To address this communication problem, hospitals now use a process called "medication reconciliation" to confirm the medications patients are taking when they enter and leave the hospital. However, the way that medication reconciliation is currently being done, patients are not actively engaged or given tools to effectively communicate the medications they are taking, changes that have been made, and what they are having trouble with. Directly engaging patients in this process might help solve this problem, and mobile technologies on smartphones may be a solution. Our study team has developed a mobile application (app) called eKidneyCare, which has a specific medication component to help patients communicate their medication information to all their doctors. This app can feed medication information from the clinic's medical record to the patient's smartphone, and any changes made to the medication list can be entered by the patient and sent back to the central server to notify their doctors. Study Design: We propose to conduct an open-label randomized controlled trial to assess the medication related effectiveness and stakeholders' satisfaction of the eKidneyCare mobile app compared to commercially available mobile apps like My MedRec for 12 months. This study will be conducted in the renal clinics at University Health Network who oversee the clinical management of advanced stage 4 to 5 CKD patients and end stage renal disease. On average, patients of this clinic are aged 65 years or more and take 10-15 medications per day. Objectives and Hypotheses Primary 1) To evaluate the effect of the eKidneyCare mobile app compared to a commercially available stand alone mobile app (My MedRec) on unintentional medication discrepancies in CKD patients. The use of the eKidneyCare app will have a greater reduction medication discrepancy rates by enhancing patient self-care through bidirectional communication of information. Secondary To determine the effect of the eKidneyCare mobile app compared to commercially available stand along mobile app (My MedRec) on CKD-specific clinical outcomes. Patients actively engaged in medication management will translate to improved clinical parameters such as better blood pressure control. To evaluate the direct costs and quality of life (QOL) associated with incorporating the eKidneyCare mobile app compared to commercially available stand along mobile app (My MedRec). Reduction in the unintentional medication discrepancy rate will offset the cost of using the medication self-care app and will improve patients' quality of life. To assess stakeholders' satisfaction in using the mobile app to manage CKD. Medication self-care app will increase satisfaction among patients. This study will evaluated if this app will decrease errors related to medications. It is hypothesized that if patients use this app to report their medications to their doctors, fewer errors will occur, which should eventually lead to reduced patient harm and healthcare use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Insufficiency, Chronic, Hypertension, Medication Reconciliation, Mobile Applications
Keywords
chronic kidney disease, mobile applications, mHealth, medication reconciliation, self-management

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
182 (Actual)

8. Arms, Groups, and Interventions

Arm Title
eKidneyCare
Arm Type
Experimental
Arm Description
The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
Arm Title
My MedRec (Commercial App)
Arm Type
Active Comparator
Arm Description
My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
Intervention Type
Other
Intervention Name(s)
Usual Care
Intervention Description
Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
Intervention Type
Device
Intervention Name(s)
Integrated mobile medication app
Intervention Description
Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
Intervention Type
Device
Intervention Name(s)
Commercially available mobile medication app
Intervention Description
Use of mobile app to manually record and maintain medication records with no integration to databases.
Primary Outcome Measure Information:
Title
Medication Discrepancy
Description
The change in unintentional medication discrepancy rate from baseline to the last (12 months) visit.
Time Frame
One year (12 months)
Secondary Outcome Measure Information:
Title
Clinic Blood Pressure
Description
Mean change in systolic and diastolic BP measured by clinic BP Tru automated machine
Time Frame
6, 12 months
Title
Ambulatory Blood Pressure
Description
Mean change in systolic and diastolic BP measured by average 7 day home ambulatory BP readings
Time Frame
12 months
Title
CKD specific laboratory values (hemoglobin)
Description
Proportion of patients in target hemoglobin, defined as hemoglobin of 100 to 120 g/L
Time Frame
12 months
Title
CKD specific laboratory values (potassium)
Description
Proportion of patients in target potassium ; defined as potassium of 3.2 to 5.0 mmol/L
Time Frame
12 months
Title
CKD specific laboratory values (phosphate)
Description
Proportion of patients in target phosphate; defined as phosphate range of less than 1.5 mmol/L.
Time Frame
12 months
Title
Medication Discrepancy Proportion of Patients
Description
Proportion of patients more than 1 unintentional discrepancy
Time Frame
12 months
Title
Satisfaction
Description
Key feedback on usability, experience and perceived strengths and weakness of mobile app
Time Frame
12 months
Title
Quality of Life
Description
Change in health utility scores as captured in the EQ-5D questionnaire
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Incident or prevalent patients who are: ≥18 years of age English-speaking Able and willing to provide informed consent Exclusion Criteria: CKD stages 1 to 3a (estimated glomerular filtration rate of ≥ 45 ml/min) likely to receive a kidney transplant within 3 months of enrollment into the trial living in a long-term care or rehabilitation institution, likely to have their care transferred to another facility outside participating clinic areas during the course of the study taking less than 2 prescription medications planning to travel or live consecutively out of the province of Ontario for more than one month participating in another intervention trial, cognitive impairment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephanie W Ong, BScPHM, MSc
Organizational Affiliation
UHN
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alexander G Logan, MD, FRCP(C)
Organizational Affiliation
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Health Network
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
33737321
Citation
Ong SW, Jassal SV, Porter EC, Min KK, Uddin A, Cafazzo JA, Rac VE, Tomlinson G, Logan AG. Digital Applications Targeting Medication Safety in Ambulatory High-Risk CKD Patients: Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol. 2021 Apr 7;16(4):532-542. doi: 10.2215/CJN.15020920. Epub 2021 Mar 18.
Results Reference
derived

Learn more about this trial

Mobile Health Technology for Chronic Kidney Disease Patients: Medication Management

We'll reach out to this number within 24 hrs